Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

• Published in: JHEP reports Vol. 5; no. 10; p. 100847
• Main Authors: Lim, Young-Suk, Chan, Henry L.Y., Ahn, Sang Hoon, Seto, Wai Kay, Ning, Qin, Agarwal, Kosh, Janssen, Harry L.A., Pan, Calvin Q., Chuang, Wan Long, Izumi, Namiki, Fung, Scott, Shalimar, Brunetto, Maurizia, Hui, Aric Josun, Chang, Ting-Tsung, Lim, Seng Gee, Abramov, Frida, Flaherty, John F., Wang, Hongyuan, Yee, Leland J., Kao, Jia-Horng, Gane, Edward, Hou, Jinlin, Buti, Maria
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.10.2023; Elsevier
• Subjects: aMAP; antiviral therapy; Gastroenterology and Hepatology; incidence; mPAGE-B; REACH-B; ETV; HBeAg; ALT; HCC; HR; mPAGE-B; SIRs; NA; aMAP; TDF; REACH-B; TAF; CHB; incidence; HBV; OL; antiviral therapy; DB; hepatitis B virus; open-label; alanine aminotransferase; tenofovir alafenamide; double-blind; hepatocellular carcinoma; chronic hepatitis B; entecavir; tenofovir disoproxil fumarate; standard incidence ratios; Hepatitis B e antigen; nucleot(s)ide analogue; hazard ratio

Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. The REACH-B, aMAP, and mPAGE-B models were utilized...